The Tipping Point

The United States has been the dominant public funder of research and development since the end of the Second World War. That position is ending. A forecast published in March 2026 by researchers at the University of California, San Diego's Frontiers in Science and Innovation Policy program projects that China will surpass the United States in government R&D spending within two to three years.^[1] This is not a distant scenario. It is the arithmetic extrapolation of a divergence that has been accumulating in the data for a decade.

Between 2013 and 2023, Chinese government R&D spending increased by 90%, reaching $133 billion on a purchasing-power-adjusted basis. Over the same period, US government spending grew by 12%, reaching $155 billion.^[2] A gap that once seemed structurally permanent is now measured in years. FSIP co-lead Robert Conn estimates the crossover at 2028, plus or minus one year.^[3] The methodology is conservative: the projection incorporates the slower Chinese growth trajectory that followed the 2020 pandemic and the subsequent property-sector contraction, rather than the 11% average annual growth rate China sustained from 2005 to 2020. If China's 7% annual spending target through 2030 holds and US appropriations continue to erode in real terms, the crossover arrives sooner.^[4]

The Variable That Matters Most

Aggregate R&D figures matter, but they are not the most consequential number. That distinction belongs to fundamental research: the basic scientific inquiry that generates knowledge with no immediate commercial application and sits at the origin of every development pipeline. FSIP co-lead Robert Conn describes it as "the seed corn that will provide the innovations and discoveries a decade from now."^[5] It is also the category where the structural gap is widening fastest.

China still trails on this measure. Its total 2023 expenditure on fundamental research, from all sources, stood at $53 billion, less than half the $120 billion recorded in the United States.^[6] The trajectories are not comparable. Chinese government spending on fundamental research more than tripled between 2013 and 2023, while comparable US spending increased by just over half.^[7] The FSIP projects that China will surpass the United States in fundamental research spending within a decade, assuming current trends hold.^[8]

Those trends are not moving in the United States' favor. The administration has proposed significant cuts to the National Science Foundation and the National Institutes of Health. The Senate has pushed back, and near-term agency budgets are expected to remain broadly flat. FSIP researchers assess that US government spending on fundamental research will nonetheless decline in real terms over the coming years as political resistance to White House budget priorities erodes.^[9] The pipeline is being drawn down at the same moment China is accelerating deposits into it.

Output Has Already Shifted

The funding crossover is not the beginning of this story. In the 145 natural-science and health-science journals tracked by Nature Index, China's research contribution is on track to be double that of the United States by the end of 2026.^[10] China now leads in 90% of critical technology areas by research output.^[11] The published knowledge base has already moved. Investment is following.

This sequence matters for how the implications should be read. Output changes in research precede industrial capability changes by years. Industrial capability changes precede economic and strategic shifts by years more. The decisions being made now about research budgets in Washington and Beijing will shape the competitive landscape in artificial intelligence, biotechnology, advanced materials, and energy technology well into the 2030s. By the time those consequences register visibly, the window for course correction will have narrowed considerably.

One methodological caution is worth acknowledging. The FSIP analysis relies on OECD data adjusted by purchasing power parity, a standard approach that accounts for the lower cost of goods and services in China relative to the United States. Some researchers argue the adjustment overstates Chinese capacity because scientific equipment and journal access are typically purchased on international markets, where Chinese purchasing power advantages do not apply.^[12] The concern is legitimate. It does not alter the directional conclusion. The divergence is too large and too sustained to attribute to statistical artifact.

Losing the Lead

There is a structural reason why the United States finds itself here, and it is not primarily a matter of fiscal discipline. It is a matter of how research investment has been framed in American policy discourse for the better part of two decades.

China has treated science funding as a strategic instrument. The evidence is in the design of the five-year plans, the construction of national laboratory infrastructure, the explicit targeting of fundamental research tripling over a decade, and the 2026 announcement of a 7% annual spending floor through 2030.^[13] The investment is not incidental to national strategy. It is the mechanism of it.

In the United States, research appropriations have been treated primarily as line items subject to the same cost-benefit scrutiny as discretionary spending on any other program. That framing is not irrational on its own terms. It becomes irrational when the time horizon of the scrutiny is mismatched to the time horizon of the investment. Fundamental research does not produce returns in the fiscal year it is appropriated. The lag between discovery and commercial application is measured in years and often decades. Evaluating science funding on short-horizon fiscal criteria is not prudence. It is a systematic undervaluation of the asset.

The compounding nature of knowledge investment amplifies this error over time. A country that sustains higher investment growth over a decade does not end up marginally ahead. It ends up with a structurally stronger base from which the next decade of compounding begins. That is the mechanism that allowed the United States to sustain scientific dominance through the latter half of the twentieth century. The same mechanism is now working in the opposite direction.

Slow Then Fast

The crossover date, whether 2027, 2028, or 2029, is less important than the structural reality it will confirm: the United States has been disinvesting from its own future productive capacity at the precise moment a strategic competitor has been systematically accelerating investment in its own. The gap is not the result of a single budget cycle or a single administration. It is the accumulated consequence of a decade of treating science as an expenditure rather than an asset.

Foundations are much easier to erode than to rebuild. The arithmetic of compounding does not wait for a policy correction to catch up.

Notes

---

1. Ben Deighton, "China could be the world's biggest public funder of science within two years," Nature Index, 19 March 2026, https://www.nature.com/articles/d41586-026-00618-5. ↩︎

2. Organisation for Economic Co-operation and Development, Main Science and Technology Indicators, purchasing-power-adjusted government R&D expenditure data, 2023. Cited in Deighton, Nature Index, 2026. ↩︎

3. Robert Conn, quoted in Deighton, Nature Index, 2026. Conn co-leads the Frontiers in Science and Innovation Policy program at the University of California, San Diego. ↩︎

4. Chinese government five-year plan announcement on R&D targets, reported in Nature, March 2026. See also Deighton, Nature Index, 2026. ↩︎

5. Conn, quoted in Deighton, Nature Index, 2026. ↩︎

6. Organisation for Economic Co-operation and Development, Main Science and Technology Indicators, 2023 fundamental research expenditure data. Cited in Deighton, Nature Index, 2026. ↩︎

7. Chinese Ministry of Finance and US National Center for Science and Engineering Statistics data, as reported in Deighton, Nature Index, 2026. ↩︎

8. Conn, quoted in Deighton, Nature Index, 2026. ↩︎

9. Christopher Martin, Explorative Science Foundation, and FSIP research team projections, as reported in Deighton, Nature Index, 2026. ↩︎

10. Nature Index country output tracking data, cited in Deighton, Nature Index, 2026. ↩︎

11. "China leads research in 90% of crucial technologies — a dramatic shift this century," Nature, 2025, https://www.nature.com/articles/d41586-025-04048-7. ↩︎

12. Yutao Sun, Dalian University of Technology, quoted in Deighton, Nature Index, 2026. ↩︎

13. Chinese government five-year plan announcement, reported in Nature, March 2026. See also Deighton, Nature Index, 2026. ↩︎